Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis

Trends in Pharmacological Sciences

Volumn 30, Issue 3, 2009, Pages 112-117

  Wallace, John L ^a   Viappiani, Serena ^b   Bolla, Manlio ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NicOx SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; NAPROXCINOD; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SMALL INTESTINE HEMORRHAGE; STOMACH HEMORRHAGE; STOMACH PROTECTION; SWINE; TREATMENT DURATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS;

EID: 61349200200     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.01.001     Document Type: Article

References (62)

1. Antman E.M., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
2. Lanas A., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
3. Serhan C.N., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21 (2007) 325-332
4. Vane J.R. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol. 51 (2000) 573-586
5. Wallace J.L., and Devchand P.R. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br. J. Pharmacol. 145 (2005) 275-282
6. Ignarro L.J., et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 9265-9269
7. Ignarro L.J. Endothelium-derived nitric oxide: actions and properties. FASEB J. 3 (1989) 31-36
8. Palmer R.M., et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
9. Wallace J.L., and Miller M.J. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 119 (2000) 512-520
10. Rees D.D., et al. Role of endothelium-derived nitric oxide in the regulation of blood pressure 3. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 3375-3378
11. Sander M., et al. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 33 (1999) 937-942
12. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 26 (2005) 33-65
13. Wallace J.L. Gastric ulceration: critical events at the neutrophil-endothelium interface. Can. J. Physiol. Pharmacol. 71 (1993) 98-102
14. Katsuyama K., et al. NO inhibits cytokine-induced iNOS expression and NF-κB activation by interfering with phosphorylation and degradation of IκB-α. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1796-1802
15. Hattori Y., et al. NO suppresses while peroxynitrite sustains NF-κB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc. Res. 63 (2004) 31-40
16. Hogaboam C.M., et al. Modulation of rat mast cell reactivity by IL-1β. Divergent effects on nitric oxide and platelet-activating factor release. J. Immunol. 151 (1993) 3767-3774
17. Huang F.P., et al. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur. J. Immunol. 28 (1998) 4062-4070
18. Davies N.M., et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 11 (1997) 69-79
19. Cicala C., et al. NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br. J. Pharmacol. 130 (2000) 1399-1405
20. Wallace J.L., et al. A diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol. 257 (1994) 249-255
21. Wallace J.L., et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107 (1994) 173-179
22. Ellis J.L., et al. NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology 12 (2005) 521-534
23. Fiorucci S., et al. Nitric oxide-releasing NSAIDs inhibit interleukin-1β converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFα. Aliment. Pharmacol. Ther. 13 (1999) 421-435
24. Elliott S.N., et al. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 109 (1995) 524-530
25. Muscara M.N., et al. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br. J. Pharmacol. 129 (2000) 681-686
26. Brzozowska I., et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J. Physiol. Pharmacol. 55 (2004) 773-790
27. Wallace J.L., et al. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J. Clin. Invest. 96 (1995) 2711-2718
28. Momi S., et al. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol. 397 (2000) 177-185
29. Muscara M.N., et al. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 62 (1998) PL235-PL240
30. Muscara M.N., et al. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H528-H535
31. Muscara M.N., et al. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br. J. Pharmacol. 133 (2001) 1314-1322
32. Rossoni G., et al. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J. Pharmacol. Exp. Ther. 310 (2004) 555-562
33. Berge O.G., et al. The CINOD AZD3582 inhibits cyclooxygenase and reduces pain, inflammation and fever in the rat. Eur. J. Pharm. Sci. 17S Suppl. (2002) S77-S78
34. Cuzzolin L., et al. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharmacol. Res. 31 (1995) 61-65
35. Fiorucci S., et al. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J. Pharmacol. Exp. Ther. 311 (2004) 1264-1271
36. Presotto C., et al. HCT 3012 reduces blood pressure in the spontaneously hypertensive rat model. Arthritis Rheum. 54 (2006) S147
37. Borg N., et al. Pharmacokinetics of AZD3582, a new COX-inhibiting nitric oxide donator (CINOD) drug, in animals support clinical potential in man. Ann. Rheum. Dis. 61 (2002) 269
38. Kaufman D.W., et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am. J. Gastroenterol. 94 (1999) 3189-3196
39. Hawkey C.J., et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 133 (2007) 57-64
40. Bolla M., et al. Naproxcinod shows different profile from naproxen in vascular tissue and cardiovascular system. Ann. Rheum. Dis. 67 (2008) 230
41. Rossoni G., et al. Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br. J. Pharmacol. 135 (2002) 1540-1546
42. Rossoni G., et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol. Res. 53 (2006) 359-366
43. Fagerholm U., et al. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. J. Pharm. Pharmacol. 57 (2005) 587-597
44. Fagerholm U., and Bjornsson M.A. Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. J. Pharm. Pharmacol. 57 (2005) 1539-1554
45. Lohmander L.S., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis. 64 (2005) 449-456
46. Schnitzer T.J., et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum. 53 (2005) 827-837
47. Schnitzer T., et al. Comparison of naproxcinod to naproxen and placebo: results of a 13-week phase 3 pivotal trial in patients with osteoarthritis of the knee with particular focus on blood pressure effects. Ann. Rheum. Dis. 67 (2008) 394
48. Hawkey C.J., et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52 (2003) 1537-1542
49. Schnitzer, et al. AZD3582, a CINOD, differs significantly from rofecoxib in having a neutral effect on blood pressure in patients with osteoarthritis: results of a randomized, controlled trial. Arthritis Rheum. 50 Suppl. (2004) 347 9
50. Berenbaum F. New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res. Ther. 10 (2008) S1
51. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol. Rev. 88 (2008) 1547-1565
52. Wallace J.L., et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119 (2000) 706-714
53. Davies N.M., et al. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment. Pharmacol. Ther. 11 (1997) 1101-1108
54. American College of Rheumatology Ad Hoc Group on Use of Selective and Non-Selective Non Steroidal Antiinflammatory Drugs (2008) Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum. 59, 1058-1073
55. Becker J.C., et al. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. Br. J. Clin. Pharmacol. 58 (2004) 587-600
56. Cote G.A., and Howden C.W. Potential adverse effects of proton pump inhibitors. Curr. Gastroenterol. Rep. 10 (2008) 208-214
57. McCarthy D.M. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?. Eur. J. Surg. 587 Suppl. (2002) 89-99
58. Grosser T., et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
59. Mitchell J.A., and Warner T.D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discov. 5 (2006) 75-86
60. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345 (2001) 433-442
61. Kearney P.M., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
62. Singh G., et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 30 (2003) 714-719